1. Efficacy in Children with Type 2 Diabetes
A late-stage trial (SURPASS-PEDS) in children and adolescents aged 10–17 showed that Mounjaro reduced HbA1c by about 2.2 percentage points compared to placebo, and also led to meaningful BMI reductions.
Eli Lilly has submitted the data to regulators to expand the indication for use in younger populations.
